Pediatric Transplant Associated Thrombotic Microangiopathy Healthcare Utilization and Implications of Eculizumab Therapy

Michelle L Schoettler,Leslie Lehmann,Pei-Chi Kao,Nan Chen,Sonata Jodele,Satheesh Chonat,Kirsten M Williams,Wendy B London,Christine Duncan,Christopher Dandoy

Blood Advances（2023）

引用 0|浏览3

暂无评分

摘要

•Among allo-HCT recipients, adjusted costs were significantly higher in high-risk TA-TMA (n=55) vs standard-risk TA-TMA (n=82).•Eculizumab was not associated with increased total costs after adjusting for GI bleeding and GVHD in HR-TA-TMA allo-HCT recipients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要